KEY POINTS
  • Oxford University spin-out company Vaccitech is working on a universal flu vaccine.
  • The company says the vaccine takes a novel approach.

A biotech spun out of Oxford University is aiming to develop a universal flu vaccine — and phase 2 trials could be completed by the end of next year.

The company, Vaccitech, says the vaccine — unlike those now found on the market — does not target surface antibodies. Instead, it works from the center of the virus where there are few components which can change the virus strain.